News & Events about Eagle Pharmaceuticals Inc.
Globe Newswire
5 months ago
WOODCLIFF LAKE, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of Delawares decision that Eagles vasopressin product ...
Ticker Report
8 months ago
BNP Paribas Arbitrage SA lessened its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX Get Rating) by 45.8% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 6,397 shares of the specialty pharmaceutical companys stock after selling 5,396 ...
Ticker Report
8 months ago
Principal Financial Group Inc. decreased its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX Get Rating) by 10.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 87,897 shares of the specialty pharmaceutical company&#...
Ticker Report
10 months ago
Equities analysts forecast that Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX Get Rating) will report earnings per share of $3.91 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Eagle Pharmaceuticals earnings, with estimates ...
Globe Newswire
10 months ago
Expects to add two U.S. Food and Drug Administration (FDA)-approved, new chemical entities (NCEs) with patent life into 2031 and expand acute care footprintCommercialized assets, BARHEMSYS (amisulpride for injection) and BYFAVO (remimazolam for injection), represent a strong strategic fit with ...